Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Lauren Blanchard

Nurse Practitioner Oakland, CA Nurse Practitioner

NPI 1326057092 CMS profile 11152682

3100 Telegraph Ave, Suite 2102, Oakland, CA 94609

Open in the dashboard

General payments

$6,652

266 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lauren Blanchard of Oakland, CA is reported in the CMS Open Payments database as having received $6,652 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $337 9
2023 General $2,533 88
2022 General $1,976 85
2021 General $1,806 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Blanchard
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lauren Blanchard were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lauren Blanchard Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,806 $135 $40–$426 $132
2022 $1,976 $152 $48–$470 $149
2023 $2,533 $166 $54–$529 $160
2024 $337 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $2,774 119 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $565 31 payments
  3. Celgene Corporation $441 20 payments
  4. Janssen Biotech, Inc. $439 12 payments
  5. Intercept Pharmaceuticals, Inc. $308 10 payments
  6. RedHill Biopharma Inc. $284 10 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $267 16 payments
  8. Ardelyx, Inc. $262 6 payments
  9. Genzyme Corporation $228 4 payments
  10. Gilead Sciences, Inc. $182 4 payments
  11. Other $902 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $6,652 266 payments
Products named General payments · program years 2021–2024
  1. CREON $923 47 payments
  2. LINZESS $854 43 payments
  3. SKYRIZI $623 14 payments
  4. MAVYRET $590 26 payments
  5. ZEPOSIA $549 21 payments
  6. STELARA $439 12 payments
  7. TRULANCE $389 20 payments
  8. HUMIRA $301 14 payments
  9. Talicia $284 10 payments
  10. XIFAXAN $280 19 payments
  11. Other $2,704 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

114

Median for Nurse Practitioner: 389

Drug cost

$1,241

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 80 $892
Famotidine Generic 34 $349

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,430

Medicare's payments for the services billed

Medicare patients

34

Average age 73

Services billed

37

21 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Diabetes 38%
Arthritis 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $99
$99 — —
TREMFYA
  • Janssen Biotech, Inc. $66
$66 — —
DUPIXENT
  • GENZYME CORPORATION $41
$41 — —
LINZESS
  • AbbVie, Inc. $34
$34 — —
CREON
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record